The infectious hemorrhagic disease known as Lassa fever, which is native to West Africa, continues to pose a serious risk to public health and has far-reaching societal and economic consequences. There is no human-use vaccination for this virus, even though it keeps popping up. The creation of vaccinations against the Lassa virus is discussed in this article as a crucial measure to reduce casualties, lessen financial losses, and strengthen international readiness for a pandemic. This study highlights the need to invest globally in Lassa virus vaccine research and distribution by looking at vaccine candidates being developed, their possible economic advantages, and their role in improving healthcare systems. Looking forward to future global health policies, the research emphasises the significance of vaccinations within the framework of pandemic preparation, learning from the experiences of COVID-19.
There are no data available for sharing in this work.
All authors declare the absence of any conflicts of interest.
All study-related tasks, from conception and design to data analysis and manuscript creation, were solely managed by the author.
No grants from public, commercial, or non-profit funding agencies supported the research, authorship, or publication of this article.
No specific software or tools were used in the research.
My gratitude goes to those who assisted in this study and manuscript preparation, and to the anonymous reviewers for their constructive insights.
-